drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00382 | DB11978 | 62 | 124 | [
"DDInter1734",
"DDInter822"
] | Tacrine | Glasdegib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
62,
24,
124
]
],
[
[
62,
24,
112
],
[
112,
23,
124
]
],
[
[
62,
24,
79
],
[
79,
24,
124
]
],
[
[
62,
63,
521
],
[
521,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib ... |
DB09049 | DB11828 | 1,135 | 1,406 | [
"DDInter1261",
"DDInter1281"
] | Naloxegol | Neratinib | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Minor | 0 | [
[
[
1135,
23,
1406
]
],
[
[
1135,
62,
392
],
[
392,
24,
1406
]
],
[
[
1135,
24,
1499
],
[
1499,
24,
1406
]
],
[
[
1135,
23,
1456
],
[
1456... | [
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Neratinib"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lapatinib"
],
[
"Lap... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine ... |
DB00477 | DB01142 | 216 | 1,264 | [
"DDInter363",
"DDInter593"
] | Chlorpromazine | Doxepin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
216,
24,
1264
]
],
[
[
216,
1,
508
],
[
508,
24,
1264
]
],
[
[
216,
40,
225
],
[
225,
1,
1264
]
],
[
[
216,
35,
401
],
[
401,
24... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a mode... | Chlorpromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Chlorpromazine (Compound) resembles Thiothixene (Compound) and Thiothixene (Compound) resembles Doxepin (Compound)
Chlorpromazine (Compound) resembles Promethazi... |
DB01211 | DB06655 | 609 | 5 | [
"DDInter393",
"DDInter1077"
] | Clarithromycin | Liraglutide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
609,
24,
5
]
],
[
[
609,
64,
1252
],
[
1252,
23,
5
]
],
[
[
609,
63,
915
],
[
915,
24,
5
]
],
[
[
609,
24,
651
],
[
651,
24,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin"
],
[
"Digo... | Clarithromycin may lead to a major life threatening interaction when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may cause... |
DB00295 | DB00501 | 475 | 752 | [
"DDInter1244",
"DDInter380"
] | Morphine | Cimetidine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
475,
24,
752
]
],
[
[
475,
6,
4973
],
[
4973,
45,
752
]
],
[
[
475,
21,
29134
],
[
29134,
60,
752
]
],
[
[
475,
25,
1664
],
[
1664,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cimetidine (Compound)
Morphine (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Morphine may lead to a major life threatening interaction when taken with Risperidone and Risperidone may cause a ... |
DB01234 | DB05679 | 1,220 | 1,683 | [
"DDInter513",
"DDInter1907"
] | Dexamethasone | Ustekinumab | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1220,
24,
1683
]
],
[
[
1220,
62,
1461
],
[
1461,
23,
1683
]
],
[
[
1220,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
1220,
25,
1362
],
[
13... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zin... |
DB06595 | DB09237 | 1,491 | 1,586 | [
"DDInter1214",
"DDInter1045"
] | Midostaurin | Levamlodipine | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1491,
24,
1586
]
],
[
[
1491,
24,
578
],
[
578,
23,
1586
]
],
[
[
1491,
63,
549
],
[
549,
24,
1586
]
],
[
[
1491,
64,
478
],
[
478,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and ... |
DB00563 | DB11828 | 663 | 1,406 | [
"DDInter1174",
"DDInter1281"
] | Methotrexate | Neratinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
663,
24,
1406
]
],
[
[
663,
24,
392
],
[
392,
24,
1406
]
],
[
[
663,
63,
1252
],
[
1252,
24,
1406
]
],
[
[
663,
25,
1510
],
[
1510,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin ... |
DB00085 | DB08938 | 639 | 1,384 | [
"DDInter1384",
"DDInter1112"
] | Pancrelipase | Magaldrate | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further informa... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
639,
24,
1384
]
],
[
[
639,
24,
954
],
[
954,
23,
1384
]
],
[
[
639,
24,
428
],
[
428,
63,
1384
]
],
[
[
639,
24,
1596
],
[
1596,
... | [
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[... | Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and ... |
DB06616 | DB15093 | 594 | 1,654 | [
"DDInter224",
"DDInter1698"
] | Bosutinib | Somapacitan | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
594,
24,
1654
]
],
[
[
594,
63,
1215
],
[
1215,
24,
1654
]
],
[
[
594,
25,
351
],
[
351,
24,
1654
]
],
[
[
594,
40,
883
],
[
883,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Bosutinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cau... |
DB01229 | DB01764 | 973 | 805 | [
"DDInter1378",
"DDInter469"
] | Paclitaxel (protein-bound) | Dalfopristin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
973,
24,
805
]
],
[
[
973,
6,
8374
],
[
8374,
45,
805
]
],
[
[
973,
63,
1101
],
[
1101,
23,
805
]
],
[
[
973,
24,
283
],
[
283,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Dalfopristin
Paclitaxel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may... |
DB00405 | DB04844 | 128 | 843 | [
"DDInter517",
"DDInter1778"
] | Dexbrompheniramine | Tetrabenazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
128,
24,
843
]
],
[
[
128,
24,
479
],
[
479,
40,
843
]
],
[
[
128,
24,
649
],
[
649,
24,
843
]
],
[
[
128,
74,
1594
],
[
1594,
2... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezi... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate inter... |
DB00983 | DB01218 | 480 | 1,493 | [
"DDInter776",
"DDInter852"
] | Formoterol | Halofantrine | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Moderate | 1 | [
[
[
480,
24,
1493
]
],
[
[
480,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
480,
7,
5998
],
[
5998,
46,
1493
]
],
[
[
480,
21,
28810
],
[
28810... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halofantrine"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Formoterol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Formoterol (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Halofantrine (Compound)
Formoterol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by ... |
DB04953 | DB09049 | 495 | 1,135 | [
"DDInter708",
"DDInter1261"
] | Ezogabine | Naloxegol | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
495,
23,
1135
]
],
[
[
495,
24,
971
],
[
971,
62,
1135
]
],
[
[
495,
63,
1424
],
[
1424,
23,
1135
]
],
[
[
495,
25,
1069
],
[
1069,
... | [
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
... | Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine ma... |
DB00460 | DB01088 | 612 | 714 | [
"DDInter1929",
"DDInter908"
] | Verteporfin | Iloprost | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
612,
24,
714
]
],
[
[
612,
24,
1479
],
[
1479,
24,
714
]
],
[
[
612,
63,
1432
],
[
1432,
24,
714
]
],
[
[
612,
24,
1637
],
[
1637,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB09570 | DB14761 | 1,480 | 242 | [
"DDInter1002",
"DDInter1578"
] | Ixazomib | Remdesivir | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1480,
24,
242
]
],
[
[
1480,
63,
467
],
[
467,
24,
242
]
],
[
[
1480,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1480,
24,
1320
],
[
1320,
... | [
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
... | Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Ixazomib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause ... |
DB00347 | DB00366 | 917 | 1,594 | [
"DDInter1871",
"DDInter600"
] | Trimethadione | Doxylamine | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Moderate | 1 | [
[
[
917,
24,
1594
]
],
[
[
917,
24,
662
],
[
662,
63,
1594
]
],
[
[
917,
18,
7212
],
[
7212,
57,
1594
]
],
[
[
917,
21,
28709
],
[
28709,
... | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],... | Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine
Trimethadione (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Doxylamine (... |
DB00436 | DB00938 | 323 | 455 | [
"DDInter179",
"DDInter1635"
] | Bendroflumethiazide | Salmeterol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
323,
24,
455
]
],
[
[
323,
24,
688
],
[
688,
63,
455
]
],
[
[
323,
21,
28722
],
[
28722,
60,
455
]
],
[
[
323,
24,
167
],
[
167,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamo... | Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Bendroflumethiazide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Salmet... |
DB00092 | DB00635 | 58 | 1,573 | [
"DDInter40",
"DDInter1515"
] | Alefacept | Prednisone | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
58,
24,
1573
]
],
[
[
58,
24,
175
],
[
175,
40,
1573
]
],
[
[
58,
24,
251
],
[
251,
1,
1573
]
],
[
[
58,
24,
1382
],
[
1382,
62,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (... |
DB00470 | DB01121 | 530 | 94 | [
"DDInter601",
"DDInter1437"
] | Dronabinol | Phenacemide | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Phenacemide is used to control certain seizures in the treatment of epilepsy. This medicine acts on the central nervous system (CNS) to reduce the number and severity of seizures. | Moderate | 1 | [
[
[
530,
24,
94
]
],
[
[
530,
24,
551
],
[
551,
1,
94
]
],
[
[
530,
24,
1364
],
[
1364,
40,
94
]
],
[
[
530,
1,
1614
],
[
1614,
24,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Phenacemide (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine (Compound) resembles Phenacemide (Compound... |
DB00647 | DB01168 | 675 | 1,053 | [
"DDInter528",
"DDInter1526"
] | Dextropropoxyphene | Procarbazine | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
675,
25,
1053
]
],
[
[
675,
18,
4930
],
[
4930,
57,
1053
]
],
[
[
675,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
675,
24,
126
],
[
126,
... | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v}... | Dextropropoxyphene (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Procarbazine (Compound)
Dextropropoxyphene (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases... |
DB00261 | DB08868 | 702 | 1,011 | [
"DDInter93",
"DDInter737"
] | Anagrelide | Fingolimod | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
702,
25,
1011
]
],
[
[
702,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
702,
23,
1247
],
[
1247,
23,
1011
]
],
[
[
702,
24,
578
],
[
578,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Sid... | Anagrelide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit ... |
DB06414 | DB09143 | 655 | 313 | [
"DDInter703",
"DDInter1701"
] | Etravirine | Sonidegib | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
655,
25,
313
]
],
[
[
655,
62,
1194
],
[
1194,
23,
313
]
],
[
[
655,
63,
837
],
[
837,
23,
313
]
],
[
[
655,
63,
478
],
[
478,
2... | [
[
[
"Etravirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Etravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
... | Etravirine may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantopraz... |
DB06210 | DB12941 | 72 | 466 | [
"DDInter631",
"DDInter481"
] | Eltrombopag | Darolutamide | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
72,
24,
466
]
],
[
[
72,
24,
351
],
[
351,
23,
466
]
],
[
[
72,
24,
159
],
[
159,
62,
466
]
],
[
[
72,
24,
738
],
[
738,
24,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and L... |
DB00951 | DB09143 | 1,072 | 313 | [
"DDInter986",
"DDInter1701"
] | Isoniazid | Sonidegib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
1072,
24,
313
]
],
[
[
1072,
24,
478
],
[
478,
24,
313
]
],
[
[
1072,
63,
597
],
[
597,
24,
313
]
],
[
[
1072,
24,
484
],
[
484,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chlora... |
DB09312 | DB08880 | 967 | 1,510 | [
"DDInter106",
"DDInter1771"
] | Antithymocyte immunoglobulin (rabbit) | Teriflunomide | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
967,
25,
1510
]
],
[
[
967,
23,
1461
],
[
1461,
23,
1510
]
],
[
[
967,
23,
1193
],
[
1193,
62,
1510
]
],
[
[
967,
24,
221
],
[
221,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with ... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Teriflunomide
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects w... |
DB00719 | DB01186 | 1,219 | 107 | [
"DDInter149",
"DDInter1430"
] | Azatadine | Pergolide | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
1219,
24,
107
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
107
]
],
[
[
1219,
63,
1594
],
[
1594,
24,
107
]
],
[
[
1219,
24,
100
],
[
100,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pergolide (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Azatadine may cause a ... |
DB06212 | DB12141 | 165 | 971 | [
"DDInter1833",
"DDInter817"
] | Tolvaptan | Gilteritinib | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
165,
24,
971
]
],
[
[
165,
23,
1135
],
[
1135,
23,
971
]
],
[
[
165,
23,
466
],
[
466,
62,
971
]
],
[
[
165,
63,
1181
],
[
1181,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Tolvaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide... |
DB01033 | DB01250 | 328 | 712 | [
"DDInter1156",
"DDInter1334"
] | Mercaptopurine | Olsalazine | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Moderate | 1 | [
[
[
328,
24,
712
]
],
[
[
328,
63,
50
],
[
50,
40,
712
]
],
[
[
328,
5,
11569
],
[
11569,
44,
712
]
],
[
[
328,
6,
11104
],
[
11104,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfasalazine"
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Mercaptopurine (Compound) treats ulcerative colitis (Disease) and ulcerative colitis (Disease) is treated by Olsalazine (Compound)
Mercaptopurine (Com... |
DB01218 | DB04953 | 1,493 | 495 | [
"DDInter852",
"DDInter708"
] | Halofantrine | Ezogabine | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Major | 2 | [
[
[
1493,
25,
495
]
],
[
[
1493,
21,
28997
],
[
28997,
60,
495
]
],
[
[
1493,
62,
112
],
[
112,
23,
495
]
],
[
[
1493,
64,
1494
],
[
1494,... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ezogabine"
]
],
[
[
"Halofantrine",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u} (Side Effec... | Halofantrine (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effe... |
DB00218 | DB01005 | 1,176 | 995 | [
"DDInter1247",
"DDInter894"
] | Moxifloxacin | Hydroxyurea | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Minor | 0 | [
[
[
1176,
23,
995
]
],
[
[
1176,
21,
29429
],
[
29429,
60,
995
]
],
[
[
1176,
1,
945
],
[
945,
62,
995
]
],
[
[
1176,
1,
739
],
[
739,
... | [
[
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side ... | Moxifloxacin (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Hydroxyurea (Compound)
Moxifloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Hydroxyurea
Moxifloxacin (Compound) ... |
DB00443 | DB09473 | 251 | 884 | [
"DDInter195",
"DDInter918"
] | Betamethasone | Indium In-111 oxyquinoline | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
251,
24,
884
]
],
[
[
251,
40,
870
],
[
870,
24,
884
]
],
[
[
251,
1,
891
],
[
891,
24,
884
]
],
[
[
251,
24,
609
],
[
609,
24,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone"... | Betamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate ... |
DB00604 | DB01041 | 1,425 | 770 | [
"DDInter385",
"DDInter1789"
] | Cisapride | Thalidomide | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1425,
24,
770
]
],
[
[
1425,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1425,
25,
609
],
[
609,
63,
770
]
],
[
[
1425,
25,
684
],
[
684,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Cisapride (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Cisapride may lead to a m... |
DB00731 | DB04575 | 1,144 | 35 | [
"DDInter1269",
"DDInter1555"
] | Nateglinide | Quinestrol | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
1144,
24,
35
]
],
[
[
1144,
63,
566
],
[
566,
1,
35
]
],
[
[
1144,
24,
984
],
[
984,
40,
35
]
],
[
[
1144,
63,
1336
],
[
1336,
4... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Quinestrol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Quinestrol (Compou... |
DB01268 | DB09080 | 1,151 | 144 | [
"DDInter1731",
"DDInter1331"
] | Sunitinib | Olodaterol | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1151,
24,
144
]
],
[
[
1151,
62,
1247
],
[
1247,
23,
144
]
],
[
[
1151,
63,
956
],
[
956,
24,
144
]
],
[
[
1151,
25,
1011
],
[
1011,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and... |
DB01218 | DB08875 | 1,493 | 1,618 | [
"DDInter852",
"DDInter262"
] | Halofantrine | Cabozantinib | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1493,
25,
1618
]
],
[
[
1493,
62,
112
],
[
112,
23,
1618
]
],
[
[
1493,
64,
723
],
[
723,
24,
1618
]
],
[
[
1493,
25,
384
],
[
384,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Halofantrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Halofantrine may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant ma... |
DB01023 | DB08820 | 409 | 1,478 | [
"DDInter716",
"DDInter997"
] | Felodipine | Ivacaftor | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
409,
24,
1478
]
],
[
[
409,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
409,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
409,
23,
1135
],
[
1135,... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Felodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Felodipine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Felodipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol m... |
DB00539 | DB01035 | 11 | 1,401 | [
"DDInter1837",
"DDInter1524"
] | Toremifene | Procainamide | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A derivative of procaine with less CNS action. | Major | 2 | [
[
[
11,
25,
1401
]
],
[
[
11,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
11,
23,
112
],
[
112,
23,
1401
]
],
[
[
11,
25,
770
],
[
770,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Comp... | Toremifene (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Proca... |
DB01076 | DB09054 | 700 | 384 | [
"DDInter133",
"DDInter905"
] | Atorvastatin | Idelalisib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
700,
24,
384
]
],
[
[
700,
24,
72
],
[
72,
24,
384
]
],
[
[
700,
63,
58
],
[
58,
24,
384
]
],
[
[
700,
40,
788
],
[
788,
24,
... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and A... |
DB05528 | DB11363 | 1,070 | 1,276 | [
"DDInter1228",
"DDInter39"
] | Mipomersen | Alectinib | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Major | 2 | [
[
[
1070,
25,
1276
]
],
[
[
1070,
64,
305
],
[
305,
24,
1276
]
],
[
[
1070,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
1070,
25,
1510
],
[
1510... | [
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alectinib"
]
],
[
[
"Mipomersen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparag... | Mipomersen may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Mipomersen may lead to a major life threatening interaction when taken with Fingolimod and... |
DB01764 | DB11979 | 805 | 1,320 | [
"DDInter469",
"DDInter625"
] | Dalfopristin | Elagolix | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
805,
24,
1320
]
],
[
[
805,
63,
608
],
[
608,
23,
1320
]
],
[
[
805,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
805,
25,
484
],
[
484,
... | [
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Dalfopristin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Elagolix
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilod... |
DB00322 | DB01101 | 141 | 60 | [
"DDInter742",
"DDInter285"
] | Floxuridine | Capecitabine | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
141,
24,
60
]
],
[
[
141,
5,
11616
],
[
11616,
44,
60
]
],
[
[
141,
6,
8569
],
[
8569,
45,
60
]
],
[
[
141,
21,
28906
],
[
28906,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Floxuridine",
"{u} (Compound) treats {v} (Disease)",
"stomach cancer"
],
[
"stomach cancer",
"{u} (Disease) i... | Floxuridine (Compound) treats stomach cancer (Disease) and stomach cancer (Disease) is treated by Capecitabine (Compound)
Floxuridine (Compound) binds TYMS (Gene) and TYMS (Gene) is bound by Capecitabine (Compound)
Floxuridine (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused b... |
DB00295 | DB08815 | 475 | 154 | [
"DDInter1244",
"DDInter1104"
] | Morphine | Lurasidone | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Major | 2 | [
[
[
475,
25,
154
]
],
[
[
475,
6,
8374
],
[
8374,
45,
154
]
],
[
[
475,
21,
29402
],
[
29402,
60,
154
]
],
[
[
475,
24,
1033
],
[
1033,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurasidone"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lurasidone"... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Morphine (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Lurasidone (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB00092 | DB00277 | 58 | 1,031 | [
"DDInter40",
"DDInter1791"
] | Alefacept | Theophylline | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
58,
24,
1031
]
],
[
[
58,
24,
523
],
[
523,
62,
1031
]
],
[
[
58,
24,
759
],
[
759,
63,
1031
]
],
[
[
58,
63,
581
],
[
581,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam may cause a minor interaction that can limit clinical effects when taken with Theophylline
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone... |
DB01192 | DB09268 | 560 | 1,662 | [
"DDInter1372",
"DDInter1464"
] | Oxymorphone | Picosulfuric acid | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
560,
24,
1662
]
],
[
[
560,
63,
1494
],
[
1494,
24,
1662
]
],
[
[
560,
24,
820
],
[
820,
24,
1662
]
],
[
[
560,
75,
475
],
[
475,
... | [
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Oxymorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
... | Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Alimemaz... |
DB00370 | DB00927 | 1,251 | 1,559 | [
"DDInter1230",
"DDInter712"
] | Mirtazapine | Famotidine | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
1251,
24,
1559
]
],
[
[
1251,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
1251,
24,
286
],
[
286,
62,
1559
]
],
[
[
1251,
23,
112
],
[
112... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Mirtazapine",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caus... | Mirtazapine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinical effects when ta... |
DB00577 | DB01024 | 1,295 | 1,096 | [
"DDInter1908",
"DDInter1252"
] | Valaciclovir | Mycophenolic acid | Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline. Valacyclovir is the L-valine ester of aciclovir. It is a member o... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Minor | 0 | [
[
[
1295,
23,
1096
]
],
[
[
1295,
18,
15501
],
[
15501,
57,
1096
]
],
[
[
1295,
21,
28666
],
[
28666,
60,
1096
]
],
[
[
1295,
1,
387
],
[
... | [
[
[
"Valaciclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Valaciclovir",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregu... | Valaciclovir (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Mycophenolic acid (Compound)
Valaciclovir (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound)
Valaciclovir (Compound) resembles Acyclovir (Com... |
DB01285 | DB01344 | 708 | 1,231 | [
"DDInter445",
"DDInter1830"
] | Corticotropin | Tolevamer | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Moderate | 1 | [
[
[
708,
24,
1231
]
],
[
[
708,
24,
961
],
[
961,
63,
1231
]
],
[
[
708,
63,
544
],
[
544,
24,
1231
]
],
[
[
708,
24,
286
],
[
286,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Licorice"
],
[... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Licorice and Licorice may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate an... |
DB11348 | DB12455 | 1,065 | 933 | [
"DDInter279",
"DDInter1336"
] | Calcium Phosphate | Omadacycline | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label]. | Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in ani... | Moderate | 1 | [
[
[
1065,
24,
933
]
],
[
[
1065,
63,
504
],
[
504,
24,
803
],
[
803,
24,
933
]
],
[
[
1065,
63,
1586
],
[
1586,
63,
803
],
[
803,
24,
... | [
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omadacycline"
]
],
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochloro... | Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium chloride and Calcium chloride may cause a moderate interaction that could exacerbate disea... |
DB00065 | DB00163 | 581 | 1,461 | [
"DDInter923",
"DDInter1943"
] | Infliximab | Vitamin E | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Minor | 0 | [
[
[
581,
23,
1461
]
],
[
[
581,
25,
76
],
[
76,
62,
1461
]
],
[
[
581,
24,
66
],
[
66,
23,
1461
]
],
[
[
581,
64,
1057
],
[
1057,
23... | [
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizu... | Infliximab may lead to a major life threatening interaction when taken with Mogamulizumab and Mogamulizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cau... |
DB11601 | DB12267 | 1,270 | 1,476 | [
"DDInter1889",
"DDInter233"
] | Tuberculin purified protein derivative | Brigatinib | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1270,
24,
1476
]
],
[
[
1270,
63,
168
],
[
168,
23,
1476
]
],
[
[
1270,
63,
629
],
[
629,
24,
1476
]
],
[
[
1270,
24,
405
],
[
405,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases ... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tuberculin purified protein derivative may cause a moderate interaction that could exa... |
DB00278 | DB06605 | 291 | 1,409 | [
"DDInter117",
"DDInter108"
] | Argatroban | Apixaban | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
291,
25,
1409
]
],
[
[
291,
6,
7524
],
[
7524,
45,
1409
]
],
[
[
291,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
291,
23,
539
],
[
539,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Argatroban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"... | Argatroban (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Apixaban (Compound)
Argatroban (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum m... |
DB01254 | DB15091 | 1,213 | 676 | [
"DDInter484",
"DDInter1901"
] | Dasatinib | Upadacitinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1213,
25,
676
]
],
[
[
1213,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1213,
63,
1249
],
[
1249,
24,
676
]
],
[
[
1213,
25,
1593
],
[
1593,... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleuc... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Naf... |
DB00373 | DB08895 | 461 | 976 | [
"DDInter1809",
"DDInter1825"
] | Timolol | Tofacitinib | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
461,
24,
976
]
],
[
[
461,
24,
407
],
[
407,
63,
976
]
],
[
[
461,
63,
475
],
[
475,
24,
976
]
],
[
[
461,
24,
868
],
[
868,
24,... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a mo... |
DB00390 | DB00804 | 1,252 | 1,507 | [
"DDInter554",
"DDInter543"
] | Digoxin | Dicyclomine | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Minor | 0 | [
[
[
1252,
23,
1507
]
],
[
[
1252,
21,
29231
],
[
29231,
60,
1507
]
],
[
[
1252,
23,
19
],
[
19,
24,
1507
]
],
[
[
1252,
23,
1511
],
[
1511... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dicyclomine"
]
],
[
[
"Digoxin",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) ... | Digoxin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Dicyclomine (Compound)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00258 | DB00390 | 666 | 1,252 | [
"DDInter270",
"DDInter554"
] | Calcium acetate | Digoxin | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Moderate | 1 | [
[
[
666,
24,
1252
]
],
[
[
666,
24,
1482
],
[
1482,
40,
1252
]
],
[
[
666,
21,
28892
],
[
28892,
60,
1252
]
],
[
[
666,
24,
1620
],
[
1620... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin (Compound) resembles Digoxin (Compound)
Calcium acetate (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Digoxin (Compound)
Calcium acetate may cause a mode... |
DB00624 | DB09054 | 1,561 | 384 | [
"DDInter1775",
"DDInter905"
] | Testosterone | Idelalisib | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1561,
24,
384
]
],
[
[
1561,
63,
305
],
[
305,
24,
384
]
],
[
[
1561,
24,
891
],
[
891,
24,
384
]
],
[
[
1561,
40,
1687
],
[
1687,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichi... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Testosterone may cause a moderate interaction that could exacerbate dise... |
DB00615 | DB12500 | 690 | 283 | [
"DDInter1589",
"DDInter714"
] | Rifabutin | Fedratinib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
690,
25,
283
]
],
[
[
690,
24,
466
],
[
466,
62,
283
]
],
[
[
690,
25,
351
],
[
351,
23,
283
]
],
[
[
690,
25,
1419
],
[
1419,
2... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutami... | Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Rifabutin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause ... |
DB00254 | DB00599 | 964 | 682 | [
"DDInter598",
"DDInter1795"
] | Doxycycline | Thiopental | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Moderate | 1 | [
[
[
964,
24,
682
]
],
[
[
964,
24,
1023
],
[
1023,
1,
682
]
],
[
[
964,
6,
8374
],
[
8374,
45,
682
]
],
[
[
964,
24,
1031
],
[
1031,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Doxycycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Thiopental (Compound)
Doxycycline may cause a moderate interaction that could ex... |
DB00446 | DB12001 | 597 | 564 | [
"DDInter351",
"DDInter7"
] | Chloramphenicol | Abemaciclib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
597,
24,
564
]
],
[
[
597,
63,
536
],
[
536,
24,
564
]
],
[
[
597,
24,
1249
],
[
1249,
24,
564
]
],
[
[
597,
24,
1017
],
[
1017,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Nafcil... |
DB06335 | DB14509 | 761 | 1,399 | [
"DDInter1646",
"DDInter1081"
] | Saxagliptin | Lithium carbonate | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
761,
24,
1399
]
],
[
[
761,
63,
874
],
[
874,
23,
1399
]
],
[
[
761,
63,
820
],
[
820,
24,
1399
]
],
[
[
761,
24,
927
],
[
927,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine ... |
DB00773 | DB06414 | 896 | 655 | [
"DDInter702",
"DDInter703"
] | Etoposide | Etravirine | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
896,
24,
655
]
],
[
[
896,
6,
4973
],
[
4973,
45,
655
]
],
[
[
896,
21,
28883
],
[
28883,
60,
655
]
],
[
[
896,
63,
1101
],
[
1101,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Etoposide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Etoposide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Etoposide (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Etravirine (Compound)
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and B... |
DB00712 | DB00959 | 1,274 | 1,486 | [
"DDInter763",
"DDInter1191"
] | Flurbiprofen | Methylprednisolone | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1274,
24,
1486
]
],
[
[
1274,
63,
175
],
[
175,
40,
1486
]
],
[
[
1274,
24,
167
],
[
167,
1,
1486
]
],
[
[
1274,
24,
617
],
[
617,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resemb... |
DB00322 | DB00978 | 141 | 739 | [
"DDInter742",
"DDInter1084"
] | Floxuridine | Lomefloxacin | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
141,
23,
739
]
],
[
[
141,
23,
945
],
[
945,
40,
739
]
],
[
[
141,
62,
1176
],
[
1176,
1,
739
]
],
[
[
141,
23,
1299
],
[
1299,
... | [
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
... | Floxuridine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (... |
DB00022 | DB00277 | 268 | 1,031 | [
"DDInter1408",
"DDInter1791"
] | Peginterferon alfa-2b | Theophylline | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
268,
24,
1031
]
],
[
[
268,
24,
1072
],
[
1072,
63,
1031
]
],
[
[
268,
24,
581
],
[
581,
24,
1031
]
],
[
[
268,
63,
491
],
[
491,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iso... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00211 | DB12500 | 1,290 | 283 | [
"DDInter1213",
"DDInter714"
] | Midodrine | Fedratinib | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1290,
24,
283
]
],
[
[
1290,
24,
401
],
[
401,
24,
283
]
],
[
[
1290,
23,
752
],
[
752,
24,
283
]
],
[
[
1290,
24,
39
],
[
39,
2... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Midodrine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimeti... |
DB00675 | DB06616 | 888 | 594 | [
"DDInter1744",
"DDInter224"
] | Tamoxifen | Bosutinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
888,
24,
594
]
],
[
[
888,
7,
2065
],
[
2065,
45,
594
]
],
[
[
888,
6,
8374
],
[
8374,
45,
594
]
],
[
[
888,
7,
7434
],
[
7434,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Tamoxifen",
"{u} (Compound) upregulates {v} (Gene)",
"SRC"
],
[
"SRC",
"{u} (Gene) is bound by {v} (Compound)",
... | Tamoxifen (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Bosutinib (Compound)
Tamoxifen (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Tamoxifen (Compound) upregulates HSD17B7 (Gene) and HSD17B7 (Gene) is upregulated by Bosutinib (Compound)
Tamoxifen (Compound) downregul... |
DB00800 | DB00902 | 572 | 104 | [
"DDInter720",
"DDInter1168"
] | Fenoldopam | Methdilazine | A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
572,
24,
104
]
],
[
[
572,
24,
820
],
[
820,
1,
104
]
],
[
[
572,
24,
401
],
[
401,
63,
104
]
],
[
[
572,
63,
274
],
[
274,
24,
... | [
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Fenoldopam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[... | Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction th... |
DB00502 | DB01177 | 1,300 | 77 | [
"DDInter853",
"DDInter904"
] | Haloperidol | Idarubicin | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
1300,
25,
77
]
],
[
[
1300,
6,
6017
],
[
6017,
45,
77
]
],
[
[
1300,
18,
2183
],
[
2183,
57,
77
]
],
[
[
1300,
21,
28803
],
[
28803,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Haloperidol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Idaru... | Haloperidol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Haloperidol (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Idarubicin (Compound)
Haloperidol (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Idarubicin (Compound)
Hal... |
DB09312 | DB06674 | 967 | 908 | [
"DDInter106",
"DDInter837"
] | Antithymocyte immunoglobulin (rabbit) | Golimumab | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
967,
64,
908
]
],
[
[
967,
23,
1193
],
[
1193,
62,
908
]
],
[
[
967,
23,
1461
],
[
1461,
23,
908
]
],
[
[
967,
24,
200
],
[
200,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}"... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Golimumab
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical eff... |
DB00334 | DB09076 | 867 | 1,116 | [
"DDInter1326",
"DDInter1899"
] | Olanzapine | Umeclidinium | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
867,
24,
1116
]
],
[
[
867,
24,
849
],
[
849,
24,
1116
]
],
[
[
867,
1,
695
],
[
695,
24,
1116
]
],
[
[
867,
40,
1408
],
[
1408,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Olanzapine (Compound) resembles Clozapine (Compound) and Clozapine may cause a moderate interaction that could... |
DB01174 | DB11978 | 697 | 124 | [
"DDInter1442",
"DDInter822"
] | Phenobarbital | Glasdegib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
697,
25,
124
]
],
[
[
697,
25,
1135
],
[
1135,
23,
124
]
],
[
[
697,
63,
112
],
[
112,
23,
124
]
],
[
[
697,
25,
466
],
[
466,
6... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u... | Phenobarbital may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may... |
DB00950 | DB11796 | 1,413 | 1,612 | [
"DDInter732",
"DDInter786"
] | Fexofenadine | Fostemsavir | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1413,
24,
1612
]
],
[
[
1413,
24,
1476
],
[
1476,
62,
1612
]
],
[
[
1413,
24,
1510
],
[
1510,
24,
1612
]
],
[
[
1413,
24,
124
],
[
124... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide and ... |
DB00295 | DB00777 | 475 | 146 | [
"DDInter1244",
"DDInter1537"
] | Morphine | Propiomazine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Major | 2 | [
[
[
475,
25,
146
]
],
[
[
475,
25,
508
],
[
508,
1,
146
]
],
[
[
475,
24,
401
],
[
401,
63,
146
]
],
[
[
475,
24,
1237
],
[
1237,
1,... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Propiomazine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Comp... | Morphine may lead to a major life threatening interaction when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate dis... |
DB00460 | DB01225 | 612 | 500 | [
"DDInter1929",
"DDInter645"
] | Verteporfin | Enoxaparin | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
612,
24,
500
]
],
[
[
612,
21,
29750
],
[
29750,
60,
500
]
],
[
[
612,
24,
1317
],
[
1317,
25,
500
]
],
[
[
612,
24,
840
],
[
840,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site pain"
],
[
"Injection site pain",
"{u}... | Verteporfin (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Enoxaparin (Compound)
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken w... |
DB01114 | DB11186 | 272 | 1,609 | [
"DDInter362",
"DDInter1427"
] | Chlorpheniramine | Pentoxyverine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
272,
24,
1609
]
],
[
[
272,
63,
314
],
[
314,
24,
1609
]
],
[
[
272,
74,
508
],
[
508,
24,
1609
]
],
[
[
272,
64,
306
],
[
306,
... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
... | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Chlorpheniramine (Compound) resembles Promazine (Compound) and Chlorpheniramine may cause a moderate in... |
DB01191 | DB09241 | 1,039 | 1,629 | [
"DDInter518",
"DDInter1186"
] | Dexfenfluramine | Methylene blue | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
1039,
25,
1629
]
],
[
[
1039,
24,
1311
],
[
1311,
24,
1629
]
],
[
[
1039,
64,
73
],
[
73,
25,
1629
]
],
[
[
1039,
25,
93
],
[
93,
... | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Dexfenfluramine may lead to a major life threatening interaction when taken with Phentermine an... |
DB00635 | DB06723 | 1,573 | 115 | [
"DDInter1515",
"DDInter58"
] | Prednisone | Aluminum hydroxide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
1573,
23,
115
]
],
[
[
1573,
21,
28643
],
[
28643,
60,
115
]
],
[
[
1573,
24,
1058
],
[
1058,
23,
115
]
],
[
[
1573,
63,
1252
],
[
125... | [
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Prednisone",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) i... | Prednisone (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril may cause a minor interaction that can limit clinical effects when taken with Alu... |
DB00247 | DB01254 | 1,131 | 1,213 | [
"DDInter1194",
"DDInter484"
] | Methysergide | Dasatinib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1131,
24,
1213
]
],
[
[
1131,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
1131,
24,
1619
],
[
1619,
63,
1213
]
],
[
[
1131,
40,
588
],
[
5... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Methysergide",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increas... | Methysergide (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerba... |
DB00047 | DB04946 | 176 | 924 | [
"DDInter932",
"DDInter907"
] | Insulin glargine | Iloperidone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
176,
24,
924
]
],
[
[
176,
24,
1664
],
[
1664,
1,
924
]
],
[
[
176,
24,
519
],
[
519,
40,
924
]
],
[
[
176,
24,
170
],
[
170,
24... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Ilo... |
DB00502 | DB11718 | 1,300 | 927 | [
"DDInter853",
"DDInter640"
] | Haloperidol | Encorafenib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1300,
25,
927
]
],
[
[
1300,
23,
112
],
[
112,
23,
927
]
],
[
[
1300,
24,
720
],
[
720,
24,
927
]
],
[
[
1300,
25,
1491
],
[
1491,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Haloperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and ... |
DB00489 | DB08865 | 17 | 1,593 | [
"DDInter1704",
"DDInter448"
] | Sotalol | Crizotinib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
17,
25,
1593
]
],
[
[
17,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
17,
24,
286
],
[
286,
63,
1593
]
],
[
[
17,
25,
455
],
[
455,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Sotalol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00700 | DB00712 | 312 | 1,274 | [
"DDInter656",
"DDInter763"
] | Eplerenone | Flurbiprofen | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
312,
24,
1274
]
],
[
[
312,
21,
28769
],
[
28769,
60,
1274
]
],
[
[
312,
64,
723
],
[
723,
24,
1274
]
],
[
[
312,
24,
1017
],
[
1017,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Eplerenone",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side... | Eplerenone (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Flurbiprofen (Compound)
Eplerenone may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Flurbi... |
DB00013 | DB00048 | 1,255 | 1,595 | [
"DDInter1905",
"DDInter435"
] | Urokinase | Collagenase clostridium histolyticum | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Moderate | 1 | [
[
[
1255,
24,
1595
]
],
[
[
1255,
24,
885
],
[
885,
63,
1595
]
],
[
[
1255,
25,
235
],
[
235,
63,
1595
]
],
[
[
1255,
64,
942
],
[
942,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epo... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum
Urokinase may lead to a major life threatening interaction when taken with Desirudi... |
DB08916 | DB12141 | 26 | 971 | [
"DDInter32",
"DDInter817"
] | Afatinib | Gilteritinib | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
26,
24,
971
]
],
[
[
26,
24,
466
],
[
466,
62,
971
]
],
[
[
26,
24,
1097
],
[
1097,
24,
971
]
],
[
[
26,
24,
242
],
[
242,
63,
... | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmid... |
DB00848 | DB14219 | 281 | 131 | [
"DDInter1044",
"DDInter1240"
] | Levamisole | Monomethyl fumarate | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Monomethyl fumarate is a dicarboxylic acid monoester resulting from the formal condensation of one of the carboxy groups of fumaric acid with methanol. Is is a metabolite of dimethyl fumarate and used for the the treatment of patients with relapsing multiple sclerosis (MS). It also induces the NFE2L2 (Nrf2) transcripti... | Moderate | 1 | [
[
[
281,
24,
131
]
],
[
[
281,
63,
58
],
[
58,
24,
304
],
[
304,
24,
131
]
],
[
[
281,
24,
1270
],
[
1270,
63,
304
],
[
304,
24,
1... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Monomethyl fumarate"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate and Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Monomethyl fuma... |
DB00434 | DB09128 | 13 | 1,241 | [
"DDInter459",
"DDInter231"
] | Cyproheptadine | Brexpiprazole | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
13,
24,
1241
]
],
[
[
13,
24,
407
],
[
407,
63,
1241
]
],
[
[
13,
24,
543
],
[
543,
24,
1241
]
],
[
[
13,
63,
1233
],
[
1233,
24... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loper... |
DB06168 | DB11581 | 1,531 | 1,456 | [
"DDInter281",
"DDInter1926"
] | Canakinumab | Venetoclax | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
1531,
24,
1456
]
],
[
[
1531,
24,
259
],
[
259,
24,
1456
]
],
[
[
1531,
24,
1129
],
[
1129,
63,
1456
]
],
[
[
1531,
63,
1683
],
[
1683... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e ... |
DB00280 | DB00572 | 494 | 85 | [
"DDInter575",
"DDInter136"
] | Disopyramide | Atropine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Moderate | 1 | [
[
[
494,
24,
85
]
],
[
[
494,
24,
19
],
[
19,
24,
85
]
],
[
[
494,
25,
1166
],
[
1166,
40,
85
]
],
[
[
494,
6,
4304
],
[
4304,
45,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Disopyramide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron (Compo... |
DB04951 | DB08880 | 187 | 1,510 | [
"DDInter1477",
"DDInter1771"
] | Pirfenidone | Teriflunomide | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
187,
25,
1510
]
],
[
[
187,
24,
1033
],
[
1033,
63,
1510
]
],
[
[
187,
24,
655
],
[
655,
24,
1510
]
],
[
[
187,
63,
752
],
[
752,
... | [
[
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpeli... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etr... |
DB00285 | DB00358 | 1,100 | 1,010 | [
"DDInter1927",
"DDInter1140"
] | Venlafaxine | Mefloquine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Moderate | 1 | [
[
[
1100,
24,
1010
]
],
[
[
1100,
6,
8374
],
[
8374,
45,
1010
]
],
[
[
1100,
21,
29362
],
[
29362,
60,
1010
]
],
[
[
1100,
24,
1311
],
[
1... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Venlafaxine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Venlafaxine (Compound) causes Leukocytosis (Side Effect) and Leukocytosis (Side Effect) is caused by Mefloquine (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopra... |
DB00783 | DB00959 | 1,438 | 1,486 | [
"DDInter679",
"DDInter1191"
] | Estradiol | Methylprednisolone | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1438,
24,
1486
]
],
[
[
1438,
63,
175
],
[
175,
40,
1486
]
],
[
[
1438,
63,
167
],
[
167,
1,
1486
]
],
[
[
1438,
24,
1220
],
[
1220,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Me... |
DB01144 | DB13928 | 1,326 | 1,385 | [
"DDInter540",
"DDInter1660"
] | Diclofenamide | Semaglutide | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1326,
24,
1385
]
],
[
[
1326,
1,
359
],
[
359,
24,
1385
]
],
[
[
1326,
63,
891
],
[
891,
24,
1385
]
],
[
[
1326,
24,
1296
],
[
1296,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may ... | Diclofenamide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate int... |
DB00220 | DB00604 | 798 | 1,425 | [
"DDInter1276",
"DDInter385"
] | Nelfinavir | Cisapride | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
798,
25,
1425
]
],
[
[
798,
24,
883
],
[
883,
1,
1425
]
],
[
[
798,
6,
21998
],
[
21998,
45,
1425
]
],
[
[
798,
7,
2216
],
[
2216,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Cisapride (Compound)
Nelfinavir (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cisapride (Compound)
Nelfinavir (Compound) upregulates PAK1 (Gene) and PA... |
DB00960 | DB01001 | 887 | 688 | [
"DDInter1471",
"DDInter1632"
] | Pindolol | Salbutamol | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Major | 2 | [
[
[
887,
25,
688
]
],
[
[
887,
64,
874
],
[
874,
24,
688
]
],
[
[
887,
1,
668
],
[
668,
64,
688
]
],
[
[
887,
63,
1636
],
[
1636,
24... | [
[
[
"Pindolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salbutamol"
]
],
[
[
"Pindolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may... | Pindolol may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Pindolol (Compound) resembles Levobunolol (Compound) and Levobunolol may lead to a major life threatening interaction when take... |
DB00014 | DB00196 | 521 | 600 | [
"DDInter839",
"DDInter743"
] | Goserelin | Fluconazole | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Moderate | 1 | [
[
[
521,
24,
600
]
],
[
[
521,
21,
28676
],
[
28676,
60,
600
]
],
[
[
521,
24,
609
],
[
609,
62,
600
]
],
[
[
521,
23,
112
],
[
112,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Nervousness"
],
[
"Nervousness",
"{u} (Side Effect) is c... | Goserelin (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Fluconazole (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken wit... |
DB00099 | DB00444 | 440 | 63 | [
"DDInter735",
"DDInter1765"
] | Filgrastim | Teniposide | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Moderate | 1 | [
[
[
440,
24,
63
]
],
[
[
440,
24,
147
],
[
147,
62,
63
]
],
[
[
440,
24,
738
],
[
738,
63,
63
]
],
[
[
440,
63,
599
],
[
599,
24,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Nirapar... |
DB00106 | DB11986 | 618 | 484 | [
"DDInter4",
"DDInter648"
] | Abarelix | Entrectinib | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
618,
24,
484
]
],
[
[
618,
23,
1247
],
[
1247,
23,
484
]
],
[
[
618,
24,
1539
],
[
1539,
24,
484
]
],
[
[
618,
24,
180
],
[
180,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Of... |
DB01611 | DB14575 | 1,487 | 733 | [
"DDInter893",
"DDInter674"
] | Hydroxychloroquine | Eslicarbazepine | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1487,
24,
733
]
],
[
[
1487,
63,
168
],
[
168,
23,
733
]
],
[
[
1487,
64,
1264
],
[
1264,
24,
733
]
],
[
[
1487,
25,
1491
],
[
1491,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortez... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Hydroxychloroquine may lead to a major life threatening interaction when taken with Doxepin and Doxep... |
DB00367 | DB00673 | 566 | 723 | [
"DDInter1061",
"DDInter112"
] | Levonorgestrel | Aprepitant | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
566,
24,
723
]
],
[
[
566,
6,
8374
],
[
8374,
45,
723
]
],
[
[
566,
21,
28642
],
[
28642,
60,
723
]
],
[
[
566,
64,
1101
],
[
1101,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aprepitant (Compound)
Levonorgestrel (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Aprepitant (Compound)
Levonorgestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.